These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33504237)

  • 41. Biologics for chronic spontaneous urticaria: toward a personalized treatment.
    Asero R; Ferrucci S; Tedeschi A; Cugno M
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1297-1305. PubMed ID: 36264653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying Patients for Self-Administration of Omalizumab.
    Murphy KR; Winders T; Smith B; Millette L; Chipps BE
    Adv Ther; 2023 Jan; 40(1):19-24. PubMed ID: 36173511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
    Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
    Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
    Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.
    Graham J; McBride D; Stull D; Halliday A; Alexopoulos ST; Balp MM; Griffiths M; Agirrezabal I; Zuberbier T; Brennan A
    Pharmacoeconomics; 2016 Aug; 34(8):815-27. PubMed ID: 27209583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.
    Denman S; El-Shanaway T; Carne E; Devlin L; Savic S
    Eur J Hosp Pharm; 2020 Nov; 27(6):367-368. PubMed ID: 33097621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biologics in Chronic Urticaria.
    Bulkhi A; Cooke AJ; Casale TB
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):95-112. PubMed ID: 27886913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
    Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
    J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Asero R
    Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up effect of omalizumab in chronic spontaneous urticaria and its association with serum C-reactive protein levels.
    Baysak S; Sevim Kecici A; Dogan B
    Dermatol Ther; 2020 Jul; 33(4):e13663. PubMed ID: 32447802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.